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Abstract: Background: High blood pressure remains one of the most important risk factors for
cardiovascular disease. Although there is no consensus, all the clinical practice guidelines agree on the
need to reduce blood pressure levels to minimize the risks. There are many clinical trials conducted to try
to find the best pharmacotherapy to achieve this goal. The aim was to compare the main international
randomized clinical trials on hypertension in people older than 50 years. Methods: Literature qualitative
review of randomized clinical trials selected from PubMed and UpToDate in people older than
50 years, from 1985 until 2020. The clinical trials conducted during this period show variability in the
drugs used, the inclusion criteria for blood pressure figures, and the consideration or not of other
vascular risk factors (smoking, obesity, lipid disorders, diabetes, and physical inactivity). Results:
Of the 8334 articles found, 19 of them fulfilled the inclusion and exclusion criteria that involved
202,638 people. The main findings of each investigation were grouped as follows: incidence of
non-cardiovascular death, death of cardiovascular origin, coronary heart disease, cerebrovascular
disease, renal failure, and hypertensive retinopathy. In all patients, blood pressure figures were
reduced, although this did not always lead to statistically significant differences in morbidity and/or
mortality risk reduction. Twelve of them found risk reduction as an effect of reduced blood pressure.
Conclusions: Randomized clinical trials conducted on hypertension in people older than 50 years
of age show variability in the inclusion criteria. Variability in the antihypertensive drugs used was
observed in this population. Blood pressure figures were reduced in all cases, although without
statistically significant differences in morbidity and/or mortality risk reduction.
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1. Introduction
Hypertension (HT) is one of the most important cardiovascular risk factors, particularly in the
United States. Second only to smoking, HT was the modifiable risk factor responsible for the largest
number of deaths from cardiovascular disease [1]. Moreover, in 2010, it was the main cause of death
and disability-affected life years worldwide [2,3]. The prevalence of HT in adults over 18 years has been
shown to range between 30 and 45%, in the case of stage 1 HT (systolic blood pressure: 140–159 mmHg,
and diastolic blood pressure: 90–99 mmHg) [2].
Studies have demonstrated the correlation between middle and old age, blood pressure (BP),
and death from cardiovascular disease, as well as providing evidence of the parallel increase between
cause and effect, with values starting at 115 mmHg for systolic blood pressure and 75 mmHg for diastolic
blood pressure [4]. When BP is reduced, mortality rates and the risk of cardiovascular complications
likewise decrease [5].
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Since 1948, when the British epidemiologist Sir Austin Bradford Hill (1897–1991) demonstrated the
causal relationship between habitual smoking and lung cancer, more than 150,000 randomized clinical
trials have been carried out in different fields of health sciences, these being necessary for licensing the
use of new drugs [6]. The most significant clinical trials began to take place in the 1980s; however,
a large number of these trials were carried out in the first decade of this century. In a significant number
of these clinical trials, the goal was to determine the reduction in the risk of various symptoms of
cardiovascular disease by reducing blood pressure, using different types of antihypertensive drugs,
or a mixture of them where necessary.
At this time, there is no review in the scientific literature of the main clinical trials on HT
that analyzes them from a qualitative perspective. The aim of this review is to compare the main
international randomized clinical trials on hypertension in adults over 50 years of age, taking into
account the pharmaceutical treatment used.
2. Experimental Section
A literature qualitative review of randomized clinical trials was carried out. The search strategy
followed was a search in PubMed (National Library of Medicine, Bethesda, MD, USA) of clinical
trials published from January 1985 to January 2020. Search terms were distributed into three blocks:
(a) health problem: “hypertension”, (b) study design: “randomized controlled trial”, (c) types of
treatment: “antihypertensive agents”, “angiotensine II type 2 receptor blockers”, “angiotensine II
type 1 receptor blockers”, “angiotensin-converting enzyme inhibitors”, “calcium channel blockers”,
“adrenergic beta-antagonists”, “diuretics”. Furthermore, the search was completed in UpToDate
(Wolters Kluwer Health, Holland).
After removing duplicate studies in the initial search, a preliminary selection was made by reading
the title and summary of each study. The original studies of those selected were obtained and subjected
to an in-depth reading in order to choose those that fulfilled inclusion and exclusion criteria. Of the
total number of clinical trials identified, those selected had been published after 1985, had a sample
size of at least 50 persons, and the interventions that were performed were multicenter and involved
one, two, or more drugs to achieve normal BP figures. Those studies in which participants were
younger than 50, that had a follow-up of less than 18 months, or that focused on particular hypertensive
patients who also had other diseases such as diabetes or chronic kidney disease were ruled out. All the
information gleaned from the documents was recorded in data collection sheets designed for this
purpose. Observational studies, revised articles, and follow-up assessments of subgroups of primary
studies were excluded. Figure 1 shows the flow chart of the selection process.
The “vote counting” method was used to display the results obtained due to the great variability of
treatments used, of BP figures, cardiovascular risk factor criteria, and results of clinical trials performed
with samples of individuals whose age was ≥50 years.
The investigation conforms to the principles outlined in the Declaration of Helsinki [7].
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3. Results
The search initially identified 8334 clinical trials, of which 19 were eventually selected to be
included in this review [8–26], involving 202,638 persons from all five continents. The features of the
studies and the patients they involved can be seen in Table 1.
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Abbreviations: ALLHAT, antihypertensive and lipid-lowering treatment to prevent heart attack trial; ARB, angiotensin II receptor blocker; CONVINCE, colchicine for prevention of
vascular inflammation in non-cardioembolic stroke; EWPHE, european working party on high blood pressure in elderly; HOPE, heart outcomes prevention evaluation; HOT, hypertension
optimal treatment study; HYVET, hypertension in the very elderly trial; AMI, acute myocardial infarction; ACE inhibitor, angiotensin-converting-enzyme inhibitor; LIFE, losartan
intervention for endpoint reduction in hypertension study; MRC-Elderly, medical research council in elderly; ONTARGET, ongoing telmisartan alone and in combination with ramipril
global endpoint trial; PROGRESS, perindopril protection against recurrent stroke study; SHEP, systolic hypertension in the elderly program; SPRINT, systolic blood pressure intervention
trial; STOP, Swedish trial in old patients with hypertension; Syst-Eur, systolic hypertension in Europe; TRANSCEND, telmisartan randomised assessment study in ace intolerant subjects
with cardiovascular disease; VALUE, valsartan antihypertensive long-term use evaluation. Source: Prepared by the author. * Intolerance to ramipril of ONTARGET study.
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The number of participants in the different clinical trials ranged between 840 in the EWPHE
(European Working Party on High blood pressure in Elderly) trial [8], from different European countries,
and 33,357 in the ALLHAT (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack
Trial) in 2002 [17], from different North American origins. The geographical and temporal distribution
of the studies was: European countries (n = 5) [8,10–12,20] during the second half of the 1980s and of
the 1990s; North American countries (n = 4) [9,14,17,24] since the beginning of the 1990s; and countries
from different continents (n = 9) [13,15,16,18,19,21–23,25] from the late 1990s to the present (Figure 2.
In this figure, the dots symbolize the number of clinical trials published each year, and the arrows link
the dots to the names of the clinical trials.).
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Raised isolated systolic BP was the criterion for participating in the SHEP (Systolic Hypertension in
the Elderly Program) [9], Syst-Eur (Systolic hypertension in Europe) [12,20], LIFE (Losartan Intervention
For Endpoint reduction in hypertension study) [16], and HYVET (Hypertension In the Very Elderly
Trial) [21] studies (n = 5) as well as in the SPRINT (Systolic blood PRessure INtervention Trial) [24] trial
and HOPE-3 (Heart Outcomes Prevention Evaluation) [25], albeit with some additional cardiovascular
risk factors (n = 2). The criterion for participating in HOT (Hypertension Optimal Treatment study) [13]
(n = 1) was having high diastolic BP, while for the studies EWPHE [8], MRC-Elderly (Medical
Research Council in Elderly) [11], STOP (Swedish Trial in Old Patients with hypertension) [10],
and VALUE (Valsartan Antihypertensive Long-term Use Evaluation) [19], the criterion was the
elevation of both the systolic and diastolic BP values (n = 4). This last criterion was required, along
with having other cardiovascular risk factors (CVRFs), in the studies ALLHAT [14,17] and CONVINCE
(COlchicine for preveNtion of Vascular INflammation in non-CardioEmbolic stroke) [18] (n = 3).
The criterion for participating in PROGRESS (Perindopril pROtection aGainst REcurrent Stroke
Study) [15], ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial) [22], TRANSCEND (Telmisartan RANdomised assessment Study in aCE iNtolerant
subjects with cardiovascular Disease) [23], and new CONVINCE [26] studies was having suffered
some type of cardiovascular disease (n = 4).
The main results that were taken into account were: death due to cardiovascular causes or any
other causes [8,10–13,16–20,22–26] (n = 15), occurrence of fatal or non-fatal cardiovascular disease from
cardiac causes [8,10–14,16–20,22–26] (n = 18), and occurrence of fatal or non-fatal cardiovascular disease
of cerebral origin [8–13,15,16,18,20–26] (n = 16) due to renal failure [12,20] (n = 2) or due to hypertensive
retinopathy or retinal haemorrhage [8,12,20] (n = 3). Some of them focused exclusively on fatal or
non-fatal strokes, such as SHEP [9], PROGRESS [15], and HYVET [21] (n = 3), while ALLHAT [14]
(n = 1) centered its principal results exclusively on the occurrence of fatal or non-fatal coronary disease.
According to the conclusions of the trials, the studies ALLHAT [17], CONVINCE [18], VALUE [19],
ONTARGET [22], TRANSCEND [23], and HOPE-3 [25] (n = 6) did not show statistically significant
differences in the results between the intervention group and the control group. STOP [10], HYVET [21],
and SPRINT [24] (n = 3) obtained a 21–43% [10,21] overall reduction in risk of mortality. EWPHE [8],
LIFE [16], and SPRINT [24] studies (n = 3) showed a 13–38% [8,16] reduction in cardiovascular
mortality risk. EWPHE [8], SHEP [9], MRC-Elderly [11], Syst-Eur [12,20], HOT [13], ALLHAT [14],
PROGRESS [15], LIFE [16], and SPRINT [24] (n = 10) showed a 13–60% [8,16] reduction in cardiovascular
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morbidity risk. Finally, SHEP [9], STOP [10], MRC-Elderly [11], Syst-Eur [12,20], PROGRESS [15],
LIFE [16], and SPRINT [24] (n = 8) showed a 13–47% [10,16] reduction in the risk of stroke.
Unlike ALLHAT [17], CONVINCE [18], VALUE [19], ONTARGET [22], TRANSCEND [23],
and HOPE-3 [25] (n = 6), which did not demonstrate any statistically significant differences between
intervention and control groups, the PROGRESS [15] and SPRINT [24] studies (n = 2)—which managed
to reduce systolic BP to a maximum value of 135 mmHg after five years of follow-up—were able
to reduce stroke risk by 28% and 25%, respectively, and cardiovascular morbidity by 26% and 25%,
respectively. The studies ALLHAT [14] and HYVET [21] (n = 2), which managed to reduce systolic
BP values to 136–140 mmHg, demonstrated a 25% reduction in cardiovascular morbidity and a 21%
reduction in overall mortality risk, respectively. For their part, those studies in which systolic BP figures
were only reduced to 141–145 mmHg [8,9,13,16,20] (n = 5) were able to reduce cardiovascular morbidity
risk by 13% (Syst-Eur [20]) and 60% (EWPHE [8]), as well as stroke risk by 13% (LIFE [16]) and 36%
(SHEP [9]). Finally, the studies that reduced systolic BP to values higher than 145 mmHg [10–12] (n = 2)
achieved a 25–43% [10,11] reduction in stroke risk.
Regarding the relationship shown between risk reduction and diastolic BP values at five years of
follow-up, only SHEP [9] and SPRINT [24] (n = 2) managed to reduce those values to 66–70 mmHg,
resulting in a 25–32% [9,24] reduction in cardiovascular morbidity risk and a 25–36% [9,24] reduction
in stroke risk. A greater number of studies [11,12,14,15,20,21] (n = 6) reduced diastolic BP figures to
76–80 mmHg, and as a result showed reductions in cardiovascular morbidity risk of between 15%
(Syst-Eur [20]) and 31% (Syst-Eur [12]), as well as a reduction in stroke risk that varied between 25%
(MRC-Elderly [11]) and 42% (Syst-Eur [12]). However, the studies (n = 4) that did not manage to lower
diastolic BP figures further than 81 mmHg [8,10,13,16] showed more uneven results, with a reduction
in overall mortality risk of between 13% (LIFE [16]) and 38% (EWPHE [8]) and in morbidity from
cardiovascular causes of between 13% (LIFE [16]) and 60% (EWPHE [8]).
Regarding the average age of the participants that took part in each of these studies, the clinical
trials [13,15] in which the average age was under 65 revealed a reduction in cardiovascular morbidity
risk of between 15% (HOT [13]) and 26% (PROGRESS [15]) (n = 2). For its part, when the average age
of the participants [14,16,24] (n = 3) was between 66 and 69, there were reductions in cardiovascular
morbidity risk that ranged from 13% (LIFE [16]) to 25% (ALLHAT [14] and SPRINT [24]). When the
average age rose to 70–74 years [8,9,11,12,20] (n = 5), the results indicated reductions in cardiovascular
morbidity of between 15% (Syst-Eur [20]) and 60% (EWPHE [8]), as well as reductions in stroke
risk of between 25% (MRC-Elderly [11]) and 42% (Syst-Eur [12]). Finally, if the average age was
over 75, there was consequently a reduction in overall mortality of between 21% (HYVET [21]) and
43% (STOP [10]) (n = 2).
4. Discussion
The first clinical trials—which were carried out in the 1980s and early 1990s and involved people
who had high BP levels, both systolic and diastolic—demonstrated a reduction in the risk of overall
mortality, cardiovascular morbidity, and fatal or non-fatal stroke [8,10]. In 1991, SHEP [9] showed,
on a large scale, that the treatment of isolated systolic HT reduced the risk of stroke by 36% (p < 0.01)
and of cardiovascular events in general by 32% (p < 0.05) when a double antihypertensive treatment
of chlorthalidone and atenolol was administered. Subsequently, several studies were carried out,
SPRINT [24] and HOPE-3 [25] being the most recent, but they only dealt with participants who also had
other CVRFs. However, prior to this, the study carried out by the Veterans Administration study group
showed that the use of a triple antihypertensive therapy also reduced cardiovascular complications by
46% [27]. In addition, the latter was designed as a multicenter study involving health professionals and
hypertensive patients from countries belonging to all five continents. For its part, the VALUE [19] study
was also carried out with the participation of professionals and individuals from all five continents,
but in this case patients with both systolic and diastolic hypertension, were included. In this sense,
the HOT [13] study was the only one that demonstrated a 15% reduction in the risk of cardiovascular
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events (p = 0.03) and a 36% reduction in acute myocardial infarction (AMI) (p = 0.002) in persons from
Europe, Asia, and America; participants were treated with felodipine and salicylate, plus an ACE
inhibitor and a beta-blocker if necessary, in persons with isolated diastolic hypertension. Nevertheless,
this treatment did not have any effect on the risk of stroke. More recently, the latest data from the
SPRINT study [28] indicate that a marked decrease in blood pressure in hypertensive persons who do
not have a history of diabetes mellitus, stroke, or congestive heart failure may increase cardiovascular
risk if the diastolic BP falls by ≤55 mmHg.
All the clinical trials analyzed compare a drug treatment with a placebo or other drugs. In every
case, a decrease in BP can be seen, leading to a reduction in cardiovascular mortality and morbidity risks.
This is true for diuretic drugs as well as ACE inhibitors, ARBs, beta-blockers, and calcium antagonists,
whether taken individually or mixed together in different combinations. In this regard, the 2016
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice [29] does not classify
these drugs according to age or sex due to lack of evidence, except for certain drugs and depending on
specific conditions. Their recommendations are directed at the beginning of antihypertensive treatment
with a combination of two drugs for persons with very high baseline BP or at high cardiovascular risk.
On the other hand, the 2017 Guideline for the Prevention, Detection, Evaluation, and Management
of High Blood Pressure in Adults [30] by the American College of Cardiology and the American
Heart Association, among other associations, recommends antihypertensive treatment with two drugs
from different groups in individuals with systolic BP levels of ≥140 mmHg or diastolic BP levels of
≥90 mmHg, and treatment with one drug if their systolic BP is 130–139 mmHg or their diastolic BP is
80–89 mmHg.
The criteria for inclusion in PROGRESS [15], ONTARGET [22], and TRANSCEND [23] studies
(together with the new edition of CONVINCE [26]), was having previously suffered one of the
following: stroke, transient ischaemic attack [15,26], coronary heart disease, peripheral artery disease,
cerebrovascular attack, or diabetes mellitus [22,23]. In the first of the three studies, perindopril and
indapamide were administered together, while in the second two, participants were given telmisartan
and ramipril together or telmisartan on its own, respectively. Neither of these two studies showed
statistically significant differences in risk reductions; however, the first did demonstrate a 28% reduction
in stroke risk (p < 0.001) and a 26% reduction in other cardiovascular events (p < 0.01).
Participants over 60 years [8–12] of age were included in the studies conducted during the 1980s
and 1990s. The HOT [13] study was the first to include individuals with HT who were aged 50 years
or older. All the studies published afterwards included men and women aged 50–55, and even the
PROGRESS study [15] did not take age into account as an inclusion criterion. The ongoing CONVINCE
study [26] reduced the lower limit for participant age to 40 years, when these participants have suffered
ischaemic cerebrovascular disease without significant disability or are at high risk of transient ischaemic
attack. The SHEP [9] and Syst-Eur [12] studies of the 1990s were the first to show the benefits of
reducing the risk of stroke and general cardiovascular events in persons aged 60 and over with isolated
systolic HT, using an antihypertensive therapy consisting of a combination of diuretic drugs and
beta-blockers in the first case, and a combination of diuretics, ACE inhibitors, and calcium antagonists
in the second.
At the other end of the age spectrum, it was not until 2008 that the HYVET study [21] demonstrated
the benefits of treating isolated systolic hypertension in people over 80 in European countries, China,
Australia, and Tunisia by reducing the risk of death from any cause using indapamide and perindropil.
Both this study and the previously mentioned SHEP study [9] in North America and the Syst-Eur
study [12] in Europe showed the benefits of an antihypertensive treatment versus placebo; this contrasted
with the nihilistic attitude that had hitherto existed, according to which the disease had to be left to take
its own course [31,32]. Studies on the subject argued that the association of HT with cardiovascular
disease risk decreases as age increases [33], and that BPs under 140/70 mmHg were associated with
increased mortality in persons over 80 years old [34]. Thus, the HYVET study helped to change this
trend, leading to treatment being offered to a larger segment of the population, such as the over 80s [35].
Nurs. Rep. 2020, 10 12
This review presents a historical recap of the main clinical trials conducted in individuals with
hypertension but without other specific pathologies from 1985 to the present, taking into account the
variability of pharmacological treatments used. It shows that, although most subjects achieve the
target blood pressure figures, a combined antihypertensive therapy is often necessary.
5. Conclusions
Randomized clinical trials conducted on hypertension in people over 50 shows variability in
terms of the inclusion criteria for patients and in the principal results, as well as a great variability in
the antihypertensive drugs used.
In all cases, blood pressure figures could be lowered, translating into a reduction in risks, although
the differences in morbidity and/or mortality reduction risks were not always statistically significant.
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